The two most widely used procedures used in Drosophila screening for genetic alterations in postmeiotic, meiotic, and premeiotic cells (and in The question arises as to how these procedures can most usefully be exploited in evaluating the potential mutagenic hazard of a compound. Three ways may be described. The simplest, although not always the most informative, is to administer the compound directly "off the shelf", by feeding, microinjection or by vacuum injection (6) . However, under these circumstances, whereas a positive response to the compound raises the possibility that the compound may be mutagenic in humans, a negative response could be due to the absence in Drosophila of the appropriate metabolic mechanism required to change the compound from a nonmutagenic to a mutagenically active form. To deal with this possible shortcoming, it would be desirable to use Drosophila in conjunction with experiments employing the conventional mammalian host mediated assay or microsomal activating systems (7). Thus, for each compound investigated, results from the Drosophila tests and those from the rodents would be evaluated, with special attention given to a comparison of the response of Drosophila to the compound, and the in vitro and in vivo responses of the indicator bacteria in the host mediated assay. The desirability of subsequently using Drosophila as an indicator organism in the host mediated assay to complement the bacterial system woild be suggested if the compound produces (a) no mutagenic effect in Drosophila or in bacteria in vitro but a positive effect in bacteria in vivo, or (b) a mutagenic effect in Drosophila and in bacteria in vitro but not in bacteria in vivo. The former suggests that the mammalian host system causes an enhancing effect, the latter suggests a detoxifying effect on the mutagenic activity of the compound (8) . It should be noted that Lee et al. (9) and Gee et al. (10) , using blood plasma or other tissues from mutagen-treated hamsters, and Browning (11) , using intraperitoneal fluid from mice, have demonstrated the utilizability of Drosophila as an indicator organ-ism in mammalian host-mediated assay systems.
Finally, in view of the findings just noted, it should not be long before Drosophila (preferably in conjunction with the conventional mouse host mediated assay or microsomal activating systems) is used to test for the possible mutagenic action of compounds found in humans, for example, therapeutic drugs, by assessing the mutationinducing ability of drug-containing body fluids taken directly from the individuals receiving these drugs.
